Peptides with the strongest published weight-loss outcomes — ranked by trial quality and FDA regulatory standing.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Weight-loss peptides are not interchangeable. GLP-1 and dual/triple incretin agonists have the most robust human trial data, while several older growth hormone and fragment peptides appear in the category despite much thinner evidence. This guide ranks the most-discussed weight-loss peptides strictly by published clinical outcomes and regulatory status.
How we ranked: Ordered by: (1) weight-loss magnitude in Phase 3 RCTs, (2) duration of evidence, (3) FDA approval status, (4) safety signal size.
Dual GIP/GLP-1 receptor agonist. In the 72-week SURMOUNT-1 Phase 3 trial, the 15 mg dose produced ~21% mean body-weight reduction in adults with obesity — the largest weight loss documented in any FDA-approved anti-obesity medication to date.
GLP-1 receptor agonist. STEP-1 (68 weeks) showed ~14.9% mean body-weight reduction at 2.4 mg/week. Longest track record of the GLP-1 class with outcomes data from cardiovascular and diabetes populations.
Triple GIP/GLP-1/glucagon receptor agonist. Phase 2 data published 2023 showed ~24.2% mean weight reduction at 48 weeks at the 12 mg dose. Not yet FDA approved — Phase 3 outcomes pending.
GHRH analog FDA-approved for HIV-associated lipodystrophy — specifically reduces visceral adipose tissue. Not a general weight-loss drug; effect is compositional rather than total-body-mass.
A modified fragment of growth hormone. Human trial evidence for weight loss is limited and largely non-replicative — a 2007 Phase 2 trial showed no significant difference vs placebo. Often marketed beyond what the data supports.
Among FDA-approved options, tirzepatide produced the largest mean weight reduction (~21% at 15 mg over 72 weeks in SURMOUNT-1). Retatrutide reported ~24% in Phase 2 but is not yet FDA approved.
No. All weight-loss peptides with meaningful clinical evidence (semaglutide, tirzepatide, retatrutide, tesamorelin) are prescription-only in the United States. Products marketed "research only" are not authorized for human use.
In pivotal GLP-1 and dual-agonist trials, measurable weight reduction appears within 4–8 weeks, with most participants continuing to lose weight through month 9–12 before plateauing. Individual response varies substantially.
No peptide has been shown to produce comparable weight loss with lower side-effect rates. Other peptides marketed for fat loss (AOD-9604, fragment peptides) lack strong human evidence.